<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114696</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/020316</org_study_id>
    <nct_id>NCT03114696</nct_id>
  </id_info>
  <brief_title>Benefit of IQP-AO-101 for Sleep</brief_title>
  <official_title>Double-blind, Placebo-controlled, Randomised Pilot Clinical Trial to Explore Benefit and Tolerability of IQP-AO-101 in Healthy Subjects With Sleep Complaints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Analyze &amp; Realize</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pilot clinical trial is to evaluate the potential of IQP-AO-101 with&#xD;
      respect to sleep-promoting effects in subjects with sleep complaints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mAIS parameters at V5 vs V2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in modified Athens Insomnia Scale parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mAIS parameter at V3 and V4, vs V2</measure>
    <time_frame>1 week, 4 weeks</time_frame>
    <description>Change in modified Athens Insomnia Scale parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activity tracker sleep parameters</measure>
    <time_frame>1 week, 6 weeks</time_frame>
    <description>Use of an activity tracker to monitor sleep and compare against baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FAIR-2</measure>
    <time_frame>1 week, 4 weeks, 6 weeks</time_frame>
    <description>Change in FAIR-2 at each visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety parameters assessed by number of subjects with abnormal laboratory values</measure>
    <time_frame>1 week, 4 weeks, 6 weeks</time_frame>
    <description>Number of subjects with abnormal laboratory values</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events that are related to treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Monitoring of adverse effects</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Insomnia, Nonorganic</condition>
  <arm_group>
    <arm_group_label>IQP-AO-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose (sachet) to be consumed 30 - 60 mins before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 dose (sachet) to be consumed 30 - 60 mins before bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AO-101</intervention_name>
    <description>1 dose (sachet) to be consumed 30 - 60 mins before bedtime</description>
    <arm_group_label>IQP-AO-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 21-65 years old&#xD;
&#xD;
          2. Non-organic moderate sleep complaints in the last year prior to V1, as per&#xD;
             investigator's judgement&#xD;
&#xD;
          3. Pittsburgh Sleep Quality Index (PSQI) score 6-15 at V1&#xD;
&#xD;
          4. Body mass index (BMI) 18.5-29.9 kg/m2&#xD;
&#xD;
          5. Generally in good health without clinically significant findings at V1&#xD;
&#xD;
          6. Readiness to comply with study procedures, in particular:&#xD;
&#xD;
               -  Consumption of the IP during the treatment period&#xD;
&#xD;
               -  Wearing activity tracker during the scheduled time periods&#xD;
&#xD;
               -  Filling in the subject diary&#xD;
&#xD;
               -  Keeping habitual diet and level of physical exercise, as well as smoking habits&#xD;
                  if applicable&#xD;
&#xD;
          7. Women of child-bearing potential:&#xD;
&#xD;
               -  Negative pregnancy testing (ß-HCG in urine) at V1&#xD;
&#xD;
               -  Commitment to use reliable contraception methods during the entire study&#xD;
&#xD;
          8. Written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known sensitivity to any components of the investigational product&#xD;
&#xD;
          2. Insomnia (according to investigator's judgement))&#xD;
&#xD;
          3. Substantial daily sleepiness as per investigator's judgement&#xD;
&#xD;
          4. Less than 5 hours sleep per night on average, self-reported at V1&#xD;
&#xD;
          5. Any medical condition associated with sleep disorder as per investigator's judgement&#xD;
             (e.g. sleep apnoea, restless legs syndrome, neurological / psychiatric disorder)&#xD;
&#xD;
          6. Any lifestyle and other factors potentially associated with sleep problems as per&#xD;
             investigator's judgement (e.g. excessive caffeine intake, shift work, long-distance&#xD;
             travelling, significant stressors such as active grieving etc.)&#xD;
&#xD;
          7. History and/or presence of clinically significant dis-ease, which per investigator's&#xD;
             judgement could interfere with the results of the study or the safety of the subject:&#xD;
&#xD;
               -  Eating disorders such as anorexia&#xD;
&#xD;
               -  Untreated or non-stabilised metabolic diseases, e.g. diabetes mellitus&#xD;
&#xD;
               -  Untreated or non-stabilised thyroid disorder&#xD;
&#xD;
               -  Untreated or non-stabilised hypertension (regular systolic blood pressure ≥140&#xD;
                  mmHg and/or diastolic blood pressure ≥90 mmHg)&#xD;
&#xD;
               -  Significant gastrointestinal diseases&#xD;
&#xD;
               -  Any other known significant or serious condition / disease that renders subjects&#xD;
                  ineligible (e.g. history of malignancy within the past 5 years prior to V1, any&#xD;
                  clinically significant cardiovascular, renal, liver disease etc.)&#xD;
&#xD;
          8. Use of drugs/supplements which could interfere with the results of the study as per&#xD;
             investigator's judgement (e.g. melatonin and melatonin derivatives, stimulants,&#xD;
             neuroleptics, benzodiazepines, antidepressants, hypnotics) within the last 4 weeks&#xD;
             prior to V1 and during the study&#xD;
&#xD;
          9. Behavioural intervention for sleep difficulties in the past 6 months and during the&#xD;
             study as per investigator's judgement&#xD;
&#xD;
         10. Deviation of laboratory parameter(s) at V1 that is:&#xD;
&#xD;
               -  clinically significant or&#xD;
&#xD;
               -  &gt;2x ULN (upper limit of normal), unless the deviation is justified by a&#xD;
                  previously known not clinically relevant condition, e.g. Gilbert's syndrome)&#xD;
&#xD;
         11. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals&#xD;
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)&#xD;
&#xD;
         12. Drug abuse&#xD;
&#xD;
         13. Participation in another study during the last 4 weeks prior to V1 and during the&#xD;
             study&#xD;
&#xD;
         14. Women of child-bearing potential: pregnant or breast-feeding&#xD;
&#xD;
         15. Any other reason for exclusion as per investigator's judgment, e.g. insufficient&#xD;
             compliance with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Analyze &amp; Realize</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

